Burgeoning Rise in Cancer Incidence: Driving Generics Market
Globally, around 12.7 Million new cancer cases were estimated in 2012. During the last decade, the global burden of cancer has significantly expanded with the incidence of new cancer cases and deaths. In such a scenario, the cost associated with cancer has also gone up. As a result, governments across the seven major pharmaceutical markets have started to prioritize their cost containment policies in order to drive costs down. Strategies are now being implemented to approve the sale of generic...
View full press release